ArticleFrontiers in molecular biosciences2025
Evaluation of changes in plasma levels of MMP-8, MMP-13, and Thrombospondin 2 in patients with Osgood-Schlatter disease (OSD).
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osgood-Schlatter disease (OSD) is characterized by its relatively frequent occurrence and unknown pathomechanism. It mainly affects young athletes. Matrix metalloproteinases (MMPs) may be involved in the pathogenesis, while Thrombospondin 2 is involved in healing process. Purpose of this study was to determine changes in MMP-8, MMP-13 and Thrombospondin 2 levels in patients with OSD compared to control group (CG). Methods: The study was conducted on 140 patients with OSD (age range: 11-15), CG consisted of 100 individuals with minor hand injuries (age range: 12-15). Levels of MMPs and Thrombospondin 2 were determined in plasma using an immunoenzymatic method (ELISA). Results: Concentrations of MMP-13 (median: 496.5 ng/mL; p < 0.0001) and Thrombospondin 2 (median: 21.05 pg/mL; p < 0.0001) were higher in patients with OSD, while MMP-8 values (median: 26.60 ng/mL; p < 0.001) were lower in patients with OSD compared to CG (58.08 ng/mL; 14.43 pg/mL; 95.91 ng/mL; respectively). Significant correlations were found between the parameters studied, and the highest AUC (area under curve) was obtained for MMP-13 in the OSD group. Discussion: The studied compounds have potential as additional tests to distinguish OSD from other diseases, and MMP-13 may be involved in the pathogenesis of OSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.